Loading
Life sciences · Journal article
Theoretical and Natural Science · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Glioblastoma (GBM) is an aggressive primary brain tumor with marked molecular and cellular heterogeneity, and current treatment provides limited long-term disease control. Single-target therapies have frequently failed because tumor subpopulations can differ in signaling dependencies, adapt under treatment pressure, and interact with a complex microenvironment. This review examines how artificial intelligence (AI) can integrate multi-omics data to improve drug-target prediction in GBM. It summarizes the pathological and molecular basis of GBM, evaluates current therapeutic targets and their limitations, and compares genomic, transcriptomic, single-cell, spatial, proteomic, metabolomic, and imaging data used for target discovery. Machine-learning, deep-learning, and network-based approaches are discussed with examples of multimodal risk stratification and candidate-target identification. The review also evaluates CRISPR screening as a functional validation step that can distinguish statistical associations from genuine tumor dependencies. Overall, AI-integrated multi-omics can provide a more context-specific approach to target prioritization by linking candidate genes to patient subgroups, cell states, and pathway activity. However, small cohorts, missing data, batch effects, limited model generalizability, and insufficient experimental validation remain major barriers. Future studies should combine larger multi-centre datasets with longitudinal and spatial profiling, interpretable models, functional perturbation, and prospective validation to support clinically translatable precision therapy in GBM.